Cardiology

Plozasiran demonstrates a 74% reduction in triglyceride levels at 24 weeks in patients with severe hypertriglyceridemia in the phase 2b SHASTA-2 trial.

Veraprapas Kittipibul, MD, discusses a study examining costs associated with heart failure hospitalization among patients with HFrEF or HFpEF from within the GWTG-HF registry.

The STEP HFpEF DM trial at ACC.24 shows significant improvements in symptoms among patients with obesity-related HFpEF and diabetes mellitus.

In this ACC.24 episode of Don't Miss a Beat, hosts are joined by Javed Butler, MD, for a breakdown of the EMPACT-MI trial.

Results of EMPACT-MI suggest use of empagliflozin was not associated with a statistically significant reduction in a composite of death and heart failure hospitalization.

Prices of nearly all insulins, SGLT2 inhibitors, and GLP1As could be reduced if robust generic or biosimilar manufacture were enabled.

Less than 2 months after being the subject of an FDA AdComm meeting, Abbott's TriClip TEER System has received approval for tricuspid regurgitation.

A recap of the biggest FDA news and decisions in cardiovascular medicine from the first 3 months of 2024, with commentary on recent announcements by Deepak Bhatt, MD, MPH, MBA.

FDA issued a warning for the the Impella left-sided blood pumps as it had received many reports of heart-wall tears, increasing the risk of death, hypertension, and more.

In a recent UK study, more than half of stroke survivors developed depression within 18 years.

The hospitalization risk was reduced to up to 75% for patients with heart disease treated with both antidepressants and psychotherapy to manage anxiety or depression symptoms.

Michael Weber, MD, lead of the PRECISION trial, discusses the significance of the aprocitentan (Tryvio) approval and key points for providers who may have patients with uncontrolled hypertension.

The approval marks the first and only once-daily single-tablet combination therapy for patients with pulmonary arterial hypertension.

Join us April 01 on Twitter for a pre-meeting Tweet chat ahead of the American College of Cardiology's 2024 annual meeting!

New data from NIH investigators show acute respiratory distress syndrome from COVID-19 infection may trigger heart inflammation in patients.

Idorsia Ltd. announced the FDA's approval of aprocitentan (Tryvio) for treatment-resistant hypertension on March 20, 2024.

Eiran Gorodeski, MD, MPH, Parag Goyal, MD, MSc, and James Fang, MD, discuss the HFSA's recent scientific statement on the prevalence and impact of cognitive impairment on the management of heart failure.

Patients whose primary care practitioners were randomized to a clinical decision support system intervention achieved a statistically significant reduction in SBP versus usual care but had similar rates of BP control.

The AccuCinch® System, utilized by Allegheny General Hospital, offers a breakthrough approach to treating heart failure by targeting the left ventricle.

A new study found women (1.64) had a greater hazard ratio of depression for CVD than men (1.39).

Eiran Gorodeski, MD, MPH, discusses a recent scientific statement composed on behalf of the Heart Failure Society of America highlighting the impact of cognitive impairment on patients with heart failure.

On March 08, 2024, the FDA approved semaglutide 2.4 mg (Wegovy) to reduce cardiovascular risk in adults with obesity or overweight and heart disease based on the SELECT trial.

On March 07, 2024, Novo Nordisk provided updates on semaglutide 2.4 mg as well as the development programs cagrisema, monlunabant, and amycretin.

A study suggests that opting for thyroid surgery or radioactive iodine therapy could be better for reducing long-term cardiovascular risk in hyperthyroidism patients compared to medication alone.

In new topline results from the KARDIA-2 trial, zilebesiran added to standard-of-care antihypertensive treatments showed significant reductions in systolic blood pressure.

Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.

In this episode, hosts are joined by SURMOUNT-2 principal investigator Timothy Garvey, MD, to discuss the approval of the tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more.

Our February 2024 cardiology month in review, recaps FDA news, top data from International Stroke Conference and major journals, and perspectives form a bevy of key opinion leaders in the field on hot topics and news from across the spectrum of cardiovascular medicine.

In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit beyond weight reduction, FLOW trial implications, and the future of incretin therapies.